<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04806230</url>
  </required_header>
  <id_info>
    <org_study_id>PAPA123</org_study_id>
    <nct_id>NCT04806230</nct_id>
  </id_info>
  <brief_title>Serum Concentrations of Antidepressant Drugs in Pregnant Women - a Naturalistic Study</brief_title>
  <acronym>PAPA</acronym>
  <official_title>Serum Concentrations of Antidepressant Drugs in Pregnant Women - a Naturalistic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Linkoeping University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Linkoeping University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was a prospective naturalistic PK study of five frequently used antidepressant&#xD;
      drugs in pregnant women; citalopram (CIT), escitalopram (ECIT), sertraline (SERT),&#xD;
      mirtazapine (MIRT) and venlafaxine VEN) and their major metabolites (Table 1). After signing&#xD;
      informed consent pregnant women with ongoing antidepressant treatment, regardless of&#xD;
      indication, were recruited at nine antenatal care centers in mid- and small cities and&#xD;
      villages in the Southeast Sweden between April 2011 and September 2013.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Serum samples for the antidepressant drug and metabolite(s) concentrations, albumin and&#xD;
      creatinine were collected at the first prenatal appointment and at gestational week 15, 20,&#xD;
      25, 35 and at partus. The time interval between drug intake and sampling was registered in&#xD;
      all cases. At partus, a serum samples from the umbilical cord was collected drug&#xD;
      concentration was assessed. At the first prenatal appointment a blood sample for analyzing&#xD;
      the CYP2D6 and CYP2C19 genotype was also collected. All drug concentration analysis were&#xD;
      executed post hoc, after last partus, whereas physiological parameters were part of normal&#xD;
      routine sampling. Concomitant medication, weight changes and smoking habits were registered&#xD;
      throughout the pregnancies.&#xD;
&#xD;
      Our main findings were that dose corrected serum concentrations of neither sertralin nor&#xD;
      citalopram changed during the pregnancy. In addition, concentrations of escitalopram and&#xD;
      venlafaxine and their metabolites appeared to be stable throughout pregnancy, even though a&#xD;
      linear mixed models statistic calculation could not be done due small number of samples.&#xD;
&#xD;
      Results from previous research on sertraline PK during pregnancy are inconclusive. Two&#xD;
      studies suggested decreased levels (Freeman, Sit 2), while one study indicated increased&#xD;
      levels (Westin). Previous studies, except for Westin's are, however, limited by small sample&#xD;
      sizes (six and eight) and a substantial inter-individual variance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2011</start_date>
  <completion_date type="Actual">September 30, 2013</completion_date>
  <primary_completion_date type="Actual">September 30, 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum concentrations of drugs and metabolites</measure>
    <time_frame>9 months</time_frame>
    <description>levels of parent compound and metabolites in serum</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">81</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Antidepressive Agents</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Observed</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sertraline, mirtazapine, venlafaxine, citalopram, escitalopram</intervention_name>
    <description>Naturalistic treatment</description>
    <arm_group_label>Observed</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        At inclusion, median age (min-max) was 31 years (21-42) and median BMI was 25.6 (18.9-47.0)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Ongoing treatment with one of the five studied antidepressants.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • None&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Linköping University</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Linkoeping University</investigator_affiliation>
    <investigator_full_name>Erik Nilzén</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>antidepressants</keyword>
  <keyword>pregnancy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirtazapine</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

